World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
27194
World Ranking
16997
National Ranking
8524

Parameswaran Hari publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Parameswaran Hari sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 802 publications — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Parameswaran Hari D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Parameswaran Hari sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 80 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Parameswaran Hari is affiliated with the Medical College of Wisconsin in the United States. Their research primarily revolves around the field of Medicine with a focus on Hematology, Oncology, Molecular Biology, Genetics, and Immunology.

The scientist's work covers key topics including:

  • Multiple Myeloma Research and Treatments
  • CAR-T cell therapy research
  • Protein Degradation and Inhibitors
  • Hematopoietic Stem Cell Transplantation
  • Chronic Lymphocytic Leukemia Research
  • Biosimilars and Bioanalytical Methods
  • Cancer Treatment and Pharmacology

Frequent co-authors collaborating with Parameswaran Hari include:

  • Saurabh Chhabra
  • Anita D'Souza
  • Binod Dhakal
  • Mehdi Hamadani
  • Saad Z. Usmani

The scientist has published extensively in several venues. Notable frequent publication venues are:

  • Blood
  • Transplantation and Cellular Therapy
  • Journal of Clinical Oncology
  • Clinical Lymphoma Myeloma & Leukemia
  • Biology of Blood and Marrow Transplantation

Some recent significant papers authored or co-authored by Parameswaran Hari include:

  • Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study (2021), The Lancet
  • Current Use of and Trends in Hematopoietic Cell Transplantation in the United States (2020), Biology of Blood and Marrow Transplantation
  • Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up (2022), Journal of Clinical Oncology
  • Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial (2020), Nature Medicine
  • Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group (2021), The Lancet Oncology

Best Publications

  • Lenalidomide after stem-cell transplantation for multiple myeloma

    Philip L. McCarthy;Kouros Owzar;Craig C. Hofmeister;David D. Hurd

  • Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

    Jesus G Berdeja;Deepu Madduri;Saad Z Usmani;Andrzej Jakubowiak

  • Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

    Sagar Lonial;Hans C Lee;Ashraf Z Badros;Suzanne Trudel

  • Current Use and Trends in Hematopoietic Cell Transplantation in the United States

    Anita D'Souza;Anita D'Souza;Stephanie Lee;Stephanie Lee;Xiaochun Zhu;Marcelo Pasquini;Marcelo Pasquini

  • Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

    Shaji Kumar;Ian Flinn;Paul G. Richardson;Parameswaran Hari

  • Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

    Ujjawal H. Gandhi;Robert F. Cornell;Arjun Lakshman;Zhubin J. Gahvari

  • Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

    Nirav N. Shah;Bryon D. Johnson;Dina Schneider;Fenlu Zhu

  • Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial

    Amrita Krishnan;Marcelo C Pasquini;Brent Logan;Edward A Stadtmauer

  • Long-Term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies

    Mohamed L. Sorror;Brenda M. Sandmaier;Brenda M. Sandmaier;Barry E. Storer;Barry E. Storer;Georg N. Franke

  • Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.

    Shaji K. Kumar;Jesus G. Berdeja;Ruben Niesvizky;Sagar Lonial

  • Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

    S. K. Kumar;M. A. Dimopoulos;E. Kastritis;E. Terpos

  • Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.

    Nilanjan Ghosh;Reem Karmali;Vanderson Rocha;Kwang Woo Ahn

  • PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: High response rate but frequent GVHD

    Bradley M. Haverkos;Diana Abbott;Mehdi Hamadani;Philippe Armand

  • Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma

    Sonali M. Smith;Linda J. Burns;Koen W. van Besien;Jennifer LeRademacher

  • Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

    Dan T Vogl;Noopur S Raje;Sundar Jagannath;Paul G. Richardson

  • Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

    Edward A. Stadtmauer;Marcelo C. Pasquini;Beth Blackwell;Parameswaran Hari

  • Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation

    Rainer Storb;Boglarka Gyurkocza;Boglarka Gyurkocza;Barry E. Storer;Barry E. Storer;Mohamed L. Sorror;Mohamed L. Sorror

  • Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

    Javier Bolaños-Meade;Ran Reshef;Raphael Fraser;Mingwei Fei

  • Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.

    Maria-Victoria Mateos;Hilary Blacklock;Fredrik Schjesvold;Albert Oriol

  • Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

    Shaji Kumar;Meletios A Dimopoulos;Efstathios Kastritis;Evangelos Terpos

Frequent Co-Authors

Marcelo C. Pasquini
Marcelo C. Pasquini Medical College of Wisconsin
Mei-Jie Zhang
Mei-Jie Zhang Medical College of Wisconsin
Shaji Kumar
Shaji Kumar Mayo Clinic
Hillard M. Lazarus
Hillard M. Lazarus Case Western Reserve University
Saad Z. Usmani
Saad Z. Usmani Memorial Sloan Kettering Cancer Center
David G. Maloney
David G. Maloney Fred Hutchinson Cancer Research Center
William R. Drobyski
William R. Drobyski Medical College of Wisconsin
Sergio Giralt
Sergio Giralt Memorial Sloan Kettering Cancer Center
Sagar Lonial
Sagar Lonial Emory University
Brenda M. Sandmaier
Brenda M. Sandmaier Fred Hutchinson Cancer Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in medical careers but want flexible study options, several accredited online degrees can help you launch or advance your healthcare journey. For Registered Nurses seeking to specialize, rn to fnp bridge programs offer a direct route from RN to Family Nurse Practitioner, supporting career growth without requiring a traditional campus setting.

For those passionate about diet, health, and wellness, earning a nutritionist online degree is a versatile way to build expert knowledge in nutrition science and qualify for rewarding roles in healthcare or the food industry.

If healthcare management is your goal, it's vital to know how to evaluate healthcare administration degree programs. Look for programs with CAHME accreditation to ensure high educational standards and optimal career outcomes.

Finally, RNs wishing to advance without on-site clinicals can consider online rn to bsn programs without clinicals. These programs offer flexible scheduling for licensed professionals eager to boost their credentials while balancing work or family commitments.

Best Scientists Citing Parameswaran Hari

Trending Scientists

Recently Published Articles